PARP1 Inhibition for Parthanatos Prevention in Neurodegeneration
📖 Wiki Page
idea1069 wordssynced 2026-04-02
Overview
This therapeutic concept targets PARP1 (Poly ADP-Ribose Polymerase 1) hyperactivation as a mechanism to prevent parthanatos, a form of programmed cell death that plays a critical role in neurodegenerative diseases, particularly Parkinson's disease.[@parp2019] PARP1 overactivation leads to mitochondrial dysfunction, NAD+ depletion, and neuronal death—making PARP1 inhibitors a promising neuroprotective strategy.
Rationale
Parthanatos in PD: The parthanatos pathway is heavily implicated in dopaminergic neuron loss in Parkinson's disease. Mitochondrial toxins (MPTP, 6-OHDA) trigger PARP1 hyperactivation leading to neuronal death.[@parthanatos2020]
NAD+ depletion: PARP1 consumes NAD+ during hyperactivation, depleting cellular energy reserves and triggering AIF-mediated cell death.[@nad2020]
Clinical momentum: PARP1 inhibitors (olaparib, niraparib, rucaparib) are approved for oncology; repurposing for neurodegeneration is feasible.[@parp2019a]
Combination potential: PARP1 inhibition synergizes with NAD+ precursors, SIRT1 activators, and mitochondrial protectants.[@synergistic2020]
Mechanistic Logic
...
Overview
This therapeutic concept targets PARP1 (Poly ADP-Ribose Polymerase 1) hyperactivation as a mechanism to prevent parthanatos, a form of programmed cell death that plays a critical role in neurodegenerative diseases, particularly Parkinson's disease.[@parp2019] PARP1 overactivation leads to mitochondrial dysfunction, NAD+ depletion, and neuronal death—making PARP1 inhibitors a promising neuroprotective strategy.
Rationale
Parthanatos in PD: The parthanatos pathway is heavily implicated in dopaminergic neuron loss in Parkinson's disease. Mitochondrial toxins (MPTP, 6-OHDA) trigger PARP1 hyperactivation leading to neuronal death.[@parthanatos2020]
NAD+ depletion: PARP1 consumes NAD+ during hyperactivation, depleting cellular energy reserves and triggering AIF-mediated cell death.[@nad2020]
Clinical momentum: PARP1 inhibitors (olaparib, niraparib, rucaparib) are approved for oncology; repurposing for neurodegeneration is feasible.[@parp2019a]
Combination potential: PARP1 inhibition synergizes with NAD+ precursors, SIRT1 activators, and mitochondrial protectants.[@synergistic2020]
Mechanistic Logic
Mermaid diagram (expand to render)
Rubric Scores
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 7 | PARP1 inhibitors approved for cancer; repurposing for neurodegeneration is emerging | | Mechanistic Rationale | 9 | Strong scientific basis; parthanatos well-characterized in PD models | | Addresses Root Cause | 8 | Targets mitochondrial dysfunction and energy crisis | | Delivery Feasibility | 6 | PARP1 inhibitors have CNS penetration challenges; prodrugs in development | | Safety Plausibility | 7 | Oncology drugs have established safety; bone marrow monitoring needed | | Combinability | 9 | Synergizes with NAD+ boosters, mitochondrial protectants, SIRT1 activators | | Biomarker Availability | 7 | PAR levels measurable; neuroimaging for neuronal survival | | De-risking Path | 8 | Existing clinical data from oncology; repurposing pathway clear | | Multi-disease Potential | 8 | PD, ALS, stroke, traumatic brain injury - all have parthanatos component | | Patient Impact | 8 | Neuroprotection is disease-modifying; addresses upstream cell death |
Total: 75/100
Actionable Next Steps
Lab Experiments
CNS-penetrant PARP inhibitor screening: Screen existing PARP inhibitors (olaparib, rucaparib, niraparib, veliparib) for brain penetration using in vitro BBB models and PK/PD in rodents
Combination synergy testing: Test PARP inhibitors combined with NAD+ precursors (NMN, NR) in iPSC-derived neurons and mouse models of AD/PD/ALS
Biomarker validation: Establish CSF PARylation as a pharmacodynamic marker
Clinical Protocol Design
Enrichment strategy: Select patients with confirmed DNA repair deficiency or elevated CSF p-tau/NfL
Dose-finding design: Start with low-dose olaparib (50-100mg daily) and escalate based on tolerability
Combination protocol: Consider adding NAD+ precursor after PARP inhibitor loading